Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2006 3
2011 1
2012 1
2014 1
2017 1
2019 1
2020 1
2021 4
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N, Ando J, Takada S, Yoshida C, Usuki K, Shinagawa A, Ishizawa K, Miyamoto T, Iida H, Dobashi N, Okubo S, Honda H, Soshin T, Nishimura Y, Tsutsui A, Mukai H, Yamamoto K. Asada N, et al. Among authors: okubo s. Jpn J Clin Oncol. 2023 Jun 29;53(7):595-603. doi: 10.1093/jjco/hyad027. Jpn J Clin Oncol. 2023. PMID: 37017320 Free PMC article. Clinical Trial.
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Okubo S, Ogawa N, Sakai M, Nishimura Y, Chyla B, Sun Y, Maruyama D. Izutsu K, et al. Among authors: okubo s. Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15. Int J Hematol. 2023. PMID: 37581752 Free PMC article. No abstract available.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I. Yamamoto K, et al. Among authors: okubo s. Jpn J Clin Oncol. 2022 Jan 3;52(1):29-38. doi: 10.1093/jjco/hyab170. Jpn J Clin Oncol. 2022. PMID: 34739075 Free PMC article. Clinical Trial.
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K. Yamauchi T, et al. Among authors: okubo s. Jpn J Clin Oncol. 2021 Aug 30;51(9):1372-1382. doi: 10.1093/jjco/hyab112. Jpn J Clin Oncol. 2021. PMID: 34322703 Free PMC article. Clinical Trial.
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I. Udagawa H, et al. Among authors: okubo s. Lung Cancer. 2019 Sep;135:145-150. doi: 10.1016/j.lungcan.2019.07.025. Epub 2019 Jul 24. Lung Cancer. 2019. PMID: 31446987 Clinical Trial.
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Izutsu K, et al. Among authors: okubo s. Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33094474 Clinical Trial.
21 results